Next Article in Journal / Special Issue
The History of Clotting Factor Concentrates Pharmacokinetics
Previous Article in Journal
Improving Communication between Physicians and Their Patients through Mindfulness and Compassion-Based Strategies: A Narrative Review
Article Menu
Issue 3 (March) cover image

Export Article

Open AccessFeature PaperArticle
J. Clin. Med. 2017, 6(3), 0034; doi:10.3390/jcm6030034

Italian Registry of Congenital Bleeding Disorders

Department of Oncology and Molecular Medicine, Istituto Superiore di Sanità, 00161 Rome
Grant Office and Technology Transfer, Istituto Superiore di Sanità, 00161 Rome
Author to whom correspondence should be addressed.
Received: 28 January 2017 / Revised: 14 March 2017 / Accepted: 15 March 2017 / Published: 19 March 2017
(This article belongs to the Special Issue Outstanding Advances in Hemophilia Therapies)
View Full-Text   |   Download PDF [1088 KB, uploaded 21 March 2017]   |  


In Italy, the surveillance of people with bleeding disorders is based on the National Registry of Congenital Coagulopathies (NRCC) managed by the Italian National Institute of Health (Istituto Superiore di Sanità). The NRCC collects epidemiological and therapeutic data from the 54 Hemophilia Treatment Centers, members of the Italian Association of Hemophilia Centres (AICE). The number of people identified with bleeding disorders has increased over the years, with the number rising from approx. 7000 in 2000 to over 11,000 in 2015. The NRCC includes 4020 patients with hemophilia A and 859 patients with hemophilia B. The prevalence of the rare type 3 vWD is 0.20/100,000 inhabitants. Less common congenital bleeding disorders include the following deficiencies: Factor I (fibrinogen), Factor II (prothrombin), Factor V, Factor VII, Factor X, Factor XI and Factor XIII, which affect 1953 patients. Hepatitis C Virus (HCV) infection affects 1561 patients, more than 200 of whom have two infections (HCV + HIV). Estimated hemophilia-related drug consumption in 2015 was approx. 550 million IU of FVIII for hemophilia A patients and approx. 70 million IU of FIX for hemophilia B patients. The NRCC, with its bleeding disorder data set, is a tool that can provide answers to fundamental questions in public health, monitoring care provision and drug treatment, as well as facilitating clinical and epidemiological research.
View Full-Text
Keywords: registry; bleeding disorders; Hemophilia A; Hemophilia B; rare diseases; clotting factors registry; bleeding disorders; Hemophilia A; Hemophilia B; rare diseases; clotting factors

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Giampaolo, A.; Abbonizio, F.; Arcieri, R.; Hassan, H.J. Italian Registry of Congenital Bleeding Disorders. J. Clin. Med. 2017, 6, 0034.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
J. Clin. Med. EISSN 2077-0383 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top